These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39374601)

  • 1. Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1.
    Bergenstal RM; Ásbjörnsdóttir B; Watt SK; Lingvay I; Mader JK; Nishida T; Rosenstock J
    Lancet Diabetes Endocrinol; 2024 Nov; 12(11):799-810. PubMed ID: 39374601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4.
    Bajaj HS; Ásbjörnsdóttir B; Carstensen L; Laugesen C; Mathieu C; Philis-Tsimikas A; Battelino T
    Diabetes Care; 2024 Apr; 47(4):729-738. PubMed ID: 38380954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
    Mathieu C; Ásbjörnsdóttir B; Bajaj HS; Lane W; Matos ALSA; Murthy S; Stachlewska K; Rosenstock J
    Lancet; 2023 Jun; 401(10392):1929-1940. PubMed ID: 37156252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
    Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
    Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    Rosenstock J; Bain SC; Gowda A; Jódar E; Liang B; Lingvay I; Nishida T; Trevisan R; Mosenzon O;
    N Engl J Med; 2023 Jul; 389(4):297-308. PubMed ID: 37356066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials.
    Bajaj HS; Ásbjörnsdóttir B; Bari TJ; Begtrup K; Vilsbøll T; Rosenstock J
    Diabetes Obes Metab; 2024 Sep; 26(9):3810-3820. PubMed ID: 38951942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.
    Goldenberg RM; Aroda VR; Billings LK; Christiansen ASL; Meller Donatsky A; Parvaresh Rizi E; Podgorski G; Raslova K; Klonoff DC; Bergenstal RM
    Diabetes Obes Metab; 2021 Nov; 23(11):2572-2581. PubMed ID: 34322967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial.
    Bajaj HS; Bergenstal RM; Christoffersen A; Davies MJ; Gowda A; Isendahl J; Lingvay I; Senior PA; Silver RJ; Trevisan R; Rosenstock J
    Diabetes Care; 2021 Jul; 44(7):1586-1594. PubMed ID: 33875485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100.
    Lingvay I; Buse JB; Franek E; Hansen MV; Koefoed MM; Mathieu C; Pettus J; Stachlewska K; Rosenstock J
    Diabetes Care; 2021 Jul; 44(7):1595-1603. PubMed ID: 33875484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
    Russell-Jones D; Babazono T; Cailleteau R; Engberg S; Irace C; Kjaersgaard MIS; Mathieu C; Rosenstock J; Woo V; Klonoff DC
    Lancet; 2023 Nov; 402(10413):1636-1647. PubMed ID: 37863084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.
    Philis-Tsimikas A; Asong M; Franek E; Jia T; Rosenstock J; Stachlewska K; Watada H; Kellerer M
    Lancet Diabetes Endocrinol; 2023 Jun; 11(6):414-425. PubMed ID: 37148899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes.
    Hövelmann U; Engberg S; Heise T; Kristensen NR; Nørgreen L; Zijlstra E; Ribel-Madsen R
    Diabetes Obes Metab; 2024 May; 26(5):1941-1949. PubMed ID: 38379002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
    Rosenstock J; Bajaj HS; Janež A; Silver R; Begtrup K; Hansen MV; Jia T; Goldenberg R;
    N Engl J Med; 2020 Nov; 383(22):2107-2116. PubMed ID: 32960514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.
    Lingvay I; Asong M; Desouza C; Gourdy P; Kar S; Vianna A; Vilsbøll T; Vinther S; Mu Y
    JAMA; 2023 Jul; 330(3):228-237. PubMed ID: 37354562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?
    Krajnc M; Kravos Tramšek NA
    Eur J Med Res; 2023 Mar; 28(1):111. PubMed ID: 36882852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.
    Aroda VR; González-Galvez G; Grøn R; Halladin N; Haluzík M; Jermendy G; Kok A; Őrsy P; Sabbah M; Sesti G; Silver R
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):596-605. PubMed ID: 31189519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes With Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Insulin-Naïve and Previously Insulin-Treated Individuals With Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials.
    Ahmed M; Shafiq A; Javaid H; Jain H; Nashwan AJ; Tul-Ain Q; Basit J
    Endocrinol Diabetes Metab; 2024 May; 7(3):e00480. PubMed ID: 38659132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials.
    Shetty S; Suvarna R
    Diabetes Obes Metab; 2024 Mar; 26(3):1069-1081. PubMed ID: 38192022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.